CymaBay Therapeutics Debt to Equity Ratio 2013-2019 | CBAY

Current and historical debt to equity ratio values for CymaBay Therapeutics (CBAY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. CymaBay Therapeutics debt/equity for the three months ending June 30, 2019 was 0.01.
CymaBay Therapeutics Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2019-06-30 $0.00B $0.24B 0.01
2019-03-31 $0.00B $0.26B 0.01
2018-12-31 $0.00B $0.17B 0.00
2018-09-30 $0.00B $0.19B 0.00
2018-06-30 $0.00B $0.20B 0.00
2018-03-31 $0.00B $0.21B 0.01
2017-12-31 $0.00B $0.09B 0.04
2017-09-30 $0.00B $0.09B 0.04
2017-06-30 $0.01B $0.00B 2.15
2017-03-31 $0.01B $0.01B 0.58
2016-12-31 $0.01B $0.00B 1.55
2016-09-30 $0.01B $0.01B 0.67
2016-06-30 $0.01B $0.02B 0.49
2016-03-31 $0.01B $0.02B 0.37
2015-12-31 $0.01B $0.03B 0.31
2015-09-30 $0.01B $0.03B 0.28
2015-06-30 $0.00B $0.02B 0.14
2015-03-31 $0.00B $0.02B 0.15
2014-12-31 $0.00B $0.01B 0.23
2014-09-30 $0.00B $0.03B 0.13
2014-06-30 $0.00B $0.01B 0.45
2014-03-31 $0.00B $0.01B 0.36
2013-12-31 $0.00B $0.02B 0.24
2013-09-30 $0.01B $0.02B 0.48
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.395B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $54.499B 9.94
Mylan (MYL) United Kingdom $11.189B 4.93
Teva Pharmaceutical Industries (TEVA) Israel $8.670B 3.41
Bausch Health Cos (BHC) Canada $8.178B 5.46
Dr Reddy's Laboratories (RDY) India $6.439B 21.67
ASPEN PHARMACR (APNHY) South Africa $2.928B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.444B 14.12
Amphastar Pharmaceuticals (AMPH) United States $1.016B 50.05
Homology Medicines (FIXX) United States $0.906B 0.00
Voyager Therapeutics (VYGR) United States $0.635B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.462B 0.00
Akorn (AKRX) United States $0.458B 0.00
Assembly Biosciences (ASMB) United States $0.292B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.283B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.277B 0.38
Adamas Pharmaceuticals (ADMS) United States $0.176B 0.00
Sol-Gel Technologies (SLGL) Israel $0.163B 0.00
Teligent (TLGT) United States $0.054B 0.00